Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
September 15, 2023 03:05 PM EDT
Pharma

No­var­tis share­hold­ers vote in fa­vor of San­doz spin­off, sep­a­ra­tion set for ear­ly Oc­to­ber

Nicole DeFeudis

Editor

No­var­tis’ San­doz spin­off is right on track fol­low­ing a share­hold­er vote in fa­vor of a full sep­a­ra­tion on Fri­day.

The gener­ics and biosim­i­lars unit is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times